{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:31:17Z","timestamp":1768455077515,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NIH R01 CA244520"],"award-info":[{"award-number":["NIH R01 CA244520"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11307-025-02048-7","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T15:25:26Z","timestamp":1758295526000},"page":"993-1005","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical Evaluation of an Anti-EphA2 Minibody-Based ImmunoPET Agent as a Diagnostic Tool For Cancer"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8501-1371","authenticated-orcid":false,"given":"Peggy A.","family":"Birikorang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. E. G.","family":"Wedaarachchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3953-8022","authenticated-orcid":false,"given":"Gary","family":"Kohanbash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6070-8778","authenticated-orcid":false,"given":"W. Barry","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"2048_CR1","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1038\/s41388-021-01714-8","volume":"40","author":"K Wilson","year":"2021","unstructured":"Wilson K, Shiuan E, Brantley-Sieders DM (2021) Oncogenic functions and therapeutic targeting of EphA2 in cancer. Oncogene 40:2483\u20132495","journal-title":"Oncogene"},{"key":"2048_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00944-9","volume":"13","author":"T Xiao","year":"2020","unstructured":"Xiao T, Xiao Y, Wang W, Tang YY, Xiao Z, Su M (2020) Targeting EphA2 in cancer. J Hematol Oncol 13:1\u201317","journal-title":"J Hematol Oncol"},{"key":"2048_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ccr.2012.11.005","volume":"22","author":"E Binda","year":"2012","unstructured":"Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, Huse JT, Cajola L, Zanetti N, DiMeco F (2012) The epha2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 22:765\u2013780","journal-title":"Cancer Cell"},{"key":"2048_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2009.04.009","volume":"16","author":"H Miao","year":"2009","unstructured":"Miao H, Li D-Q, Mukherjee A, Guo H, Petty A, Cutter J, Basilion JP, Sedor J, Wu J, Danielpour D (2009) EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16:9\u201320","journal-title":"Cancer Cell"},{"key":"2048_CR5","first-page":"151","volume":"19","author":"L-F Wang","year":"2008","unstructured":"Wang L-F, Fokas E, Bieker M, Rose F, Rexin P, Zhu Y, Pagenstecher A, Engenhart-Cabillic R, An H-X (2008) Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep 19:151\u2013156","journal-title":"Oncol Rep"},{"key":"2048_CR6","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1172\/JCI127755","volume":"129","author":"N Markosyan","year":"2019","unstructured":"Markosyan N, Li J, Sun YH, Richman LP, Lin JH, Yan F, Quinones L, Sela Y, Yamazoe T, Gordon N (2019) Tumor cell\u2013intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2). J Clin Invest 129:3594\u20133609","journal-title":"J Clin Invest"},{"key":"2048_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jgg.2021.02.011","volume":"48","author":"P Zhao","year":"2021","unstructured":"Zhao P, Jiang D, Huang Y, Chen C (2021) EphA2: a promising therapeutic target in breast cancer. J Genet Genom 48:261\u2013267","journal-title":"J Genet Genom"},{"key":"2048_CR8","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1158\/1535-7163.MCT-19-1092","volume":"19","author":"G Bennett","year":"2020","unstructured":"Bennett G, Brown A, Mudd G, Huxley P, Van Rietschoten K, Pavan S, Chen L, Watcham S, Lahdenranta J, Keen N (2020) MMAE delivery using the bicycle toxin conjugate BT5528. Mol Cancer Ther 19:1385\u20131394","journal-title":"Mol Cancer Ther"},{"key":"2048_CR9","doi-asserted-by":"publisher","first-page":"9367","DOI":"10.1158\/0008-5472.CAN-08-1933","volume":"68","author":"D Jackson","year":"2008","unstructured":"Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M, Fazenbaker C, Fleming R, Swamynathan S, Meyer D (2008) A human antibody\u2013drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res 68:9367\u20139374","journal-title":"Cancer Res"},{"key":"2048_CR10","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1021\/jm201743s","volume":"55","author":"S Wang","year":"2012","unstructured":"Wang S, Placzek WJ, Stebbins JL, Mitra S, Noberini R, Koolpe M, Zhang Z, Dahl R, Pasquale EB, Pellecchia M (2012) Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells. J Med Chem 55:2427\u20132436","journal-title":"J Med Chem"},{"key":"2048_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.tranon.2017.10.009","volume":"11","author":"N Li","year":"2018","unstructured":"Li N, Liu S, Sun M, Chen W, Xu X, Zeng Z, Tang Y, Dong Y, Chang AH, Zhao Q (2018) Chimeric antigen receptor-modified T cells redirected to EphA2 for the immunotherapy of non-small cell lung cancer. Transl Oncol 11:11\u201317","journal-title":"Transl Oncol"},{"key":"2048_CR12","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/cncr.22958","volume":"110","author":"S Yamaguchi","year":"2007","unstructured":"Yamaguchi S, Tatsumi T, Takehara T, Sakamori R, Uemura A, Mizushima T, Ohkawa K, Storkus WJ, Hayashi N (2007) Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer 110:1469\u20131477","journal-title":"Cancer"},{"key":"2048_CR13","doi-asserted-by":"publisher","DOI":"10.2310\/7290.2015.00008","volume":"14","author":"S Puttick","year":"2015","unstructured":"Puttick S, Stringer BW, Day BW, Bruce ZC, Ensbey KS, Mardon K, Cowin GJ, Thurecht KJ, Whittaker AK, Fay M (2015) EphA2 as a diagnostic imaging target in glioblastoma: a positron emission tomography\/magnetic resonance imaging study. Mol Imaging 14:7290.2015. 00008","journal-title":"Mol Imaging"},{"key":"2048_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2022.104211","volume":"15","author":"B Qu","year":"2022","unstructured":"Qu B, Han Y, Liang T, Zhang C, Hou G, Gao F (2022) Evaluation of a novel EphA2 targeting peptide for triple negative breast cancer based on radionuclide molecular imaging. Arab J Chem 15:104211","journal-title":"Arab J Chem"},{"key":"2048_CR15","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/s41416-022-01860-0","volume":"127","author":"E Tomiyama","year":"2022","unstructured":"Tomiyama E, Fujita K, Matsuzaki K, Narumi R, Yamamoto A, Uemura T, Yamamichi G, Koh Y, Matsushita M, Hayashi Y (2022) EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer. Br J Cancer 127:1312\u20131323","journal-title":"Br J Cancer"},{"key":"2048_CR16","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1002\/cmdc.201800624","volume":"13","author":"R Fu","year":"2018","unstructured":"Fu R, Carroll L, Yahioglu G, Aboagye EO, Miller PW (2018) Antibody fragment and affibody immunoPET imaging agents: radiolabelling strategies and applications. ChemMedChem 13:2466\u20132478","journal-title":"ChemMedChem"},{"key":"2048_CR17","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1200\/JCO.2012.42.4887","volume":"30","author":"SM Knowles","year":"2012","unstructured":"Knowles SM, Wu AM (2012) Advances in immuno\u2013positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol 30:3884","journal-title":"J Clin Oncol"},{"key":"2048_CR18","first-page":"3055","volume":"56","author":"S-z Hu","year":"1996","unstructured":"Hu S-z, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, Shively JE, Wu AM (1996) Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56:3055\u20133061","journal-title":"Cancer Res"},{"key":"2048_CR19","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.2967\/jnumed.108.060426","volume":"50","author":"T Olafsen","year":"2009","unstructured":"Olafsen T, Betting D, Kenanova VE, Salazar FB, Clarke P, Said J, Raubitschek AA, Timmerman JM, Wu AM (2009) Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med 50:1500\u20131508","journal-title":"J Nucl Med"},{"key":"2048_CR20","first-page":"1962","volume":"44","author":"G Sundaresan","year":"2003","unstructured":"Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, Williams LE, Chatziioannou AF, Gambhir SS, Wu AM (2003) 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 44:1962\u20131969","journal-title":"J Nucl Med"},{"key":"2048_CR21","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1038\/s41598-018-23481-5","volume":"8","author":"J Seijsing","year":"2018","unstructured":"Seijsing J, Yu S, Frejd FY, H\u00f6iden-Guthenberg I, Gr\u00e4slund T (2018) In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor. Sci Rep 8:5141","journal-title":"Sci Rep"},{"key":"2048_CR22","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/eji.1830160727","volume":"16","author":"P Vieira","year":"1986","unstructured":"Vieira P, Rajewsky K (1986) The bulk of endogenously produced IgG2a is eliminated from the serum of adult C57BL\/6 mice with a half-life of 6\u20138 days. Eur J Immunol 16:871\u2013874","journal-title":"Eur J Immunol"},{"key":"2048_CR23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/eji.1830180221","volume":"18","author":"P Vieira","year":"1988","unstructured":"Vieira P, Rajewsky K (1988) The half-lives of serum immunoglobulins in adult mice. Eur J Immunol 18:313\u2013316","journal-title":"Eur J Immunol"},{"key":"2048_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1053\/j.semnuclmed.2009.12.005","volume":"40","author":"T Olafsen","year":"2010","unstructured":"Olafsen T, Wu AM (2010) Antibody vectors for imaging. Semin Nucl Med 40:167\u2013181","journal-title":"Semin Nucl Med"},{"key":"2048_CR25","first-page":"720","volume":"63","author":"MD Farwell","year":"2022","unstructured":"Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, Mascioni A, Le W, Wilson I, Gordon MS (2022) CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: a phase I first-in-humans study of 89Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody. J Nucl Med 63:720\u2013726","journal-title":"J Nucl Med"},{"key":"2048_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2967\/jnumed.119.229781","volume":"61","author":"N Pandit-Taskar","year":"2020","unstructured":"Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O\u2019Donoghue JA, Ziolkowska M, Ruan S, Lyashchenko SK, Tsai F (2020) First-in-humans imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting. J Nucl Med 61:512\u2013519","journal-title":"J Nucl Med"},{"key":"2048_CR27","unstructured":"Kinch MS, Wu H, Bachy C, Tice D, Gao C\u00a0(2009)\u00a0Toxin conjugated\u00a0Eph\u00a0receptor antibodies. MedImmune LLC & Seattle Genetics Inc: United States, US20090304721A1"},{"key":"2048_CR28","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","volume":"10","author":"KJ Hamblett","year":"2004","unstructured":"Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10:7063\u20137070","journal-title":"Clin Cancer Res"},{"key":"2048_CR29","doi-asserted-by":"publisher","first-page":"6419","DOI":"10.1021\/acs.jmedchem.1c02044","volume":"65","author":"U Karczmarczyk","year":"2022","unstructured":"Karczmarczyk U, Sawicka A, Garnuszek P, Maurin M, Wojdowska W (2022) Does the number of bifunctional chelators conjugated to a mAb affect the biological activity of its radio-labeled counterpart? Discussion using the example of mAb against CD-20 labeled with 90Y or 177Lu. J Med Chem 65:6419\u20136430","journal-title":"J Med Chem"},{"key":"2048_CR30","first-page":"878","volume":"55","author":"DL Kukis","year":"1995","unstructured":"Kukis DL, DeNardo GL, DeNardo SJ, Mirick GR, Miers LA, Greiner DP, Meares CF (1995) Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res 55:878\u2013884","journal-title":"Cancer Res"},{"key":"2048_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.nucmedbio.2019.04.005","volume":"71","author":"SK Sharma","year":"2019","unstructured":"Sharma SK, Lyashchenko SK, Park HA, Pillarsetty N, Roux Y, Wu J, Poty S, Tully KM, Poirier JT, Lewis JS (2019) A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals. Nucl Med Biol 71:32\u201338","journal-title":"Nucl Med Biol"},{"key":"2048_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-2-40","volume":"2","author":"M Hatano","year":"2004","unstructured":"Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, Storkus WJ, Okada H (2004) Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med 2:1\u20139","journal-title":"J Transl Med"},{"key":"2048_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00418-016-1494-8","volume":"147","author":"N Konda","year":"2017","unstructured":"Konda N, Saeki N, Nishino S, Ogawa K (2017) Truncated EphA2 likely potentiates cell adhesion via integrins as well as infiltration and\/or lodgment of a monocyte\/macrophage cell line in the red pulp and marginal zone of the mouse spleen, where ephrin-A1 is prominently expressed in the vasculature. Histochem Cell Biol 147:317\u2013339","journal-title":"Histochem Cell Biol"},{"key":"2048_CR34","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00259-010-1433-1","volume":"37","author":"EJ Lepin","year":"2010","unstructured":"Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks JD, Reiter RE, Wu AM (2010) An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imag 37:1529\u20131538","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2048_CR35","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.e16057","author":"T Olafsen","year":"2014","unstructured":"Olafsen T, Bartlett D, Ho D, Zhang G, Torgov M, Keppler J, Behrenbruch C, Wu A, Pandit-Taskar N, Morris MJ (2014) Minibody imaging of prostate-specific membrane antigen (PSMA): from concept to clinic. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.e16057","journal-title":"J Clin Oncol"},{"key":"2048_CR36","doi-asserted-by":"publisher","first-page":"5907","DOI":"10.1158\/0008-5472.CAN-04-4472","volume":"65","author":"T Olafsen","year":"2005","unstructured":"Olafsen T, Kenanova VE, Sundaresan G, Anderson A-L, Crow D, Yazaki PJ, Li L, Press MF, Gambhir SS, Williams LE (2005) Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 65:5907\u20135916","journal-title":"Cancer Res"},{"key":"2048_CR37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s12149-018-1312-6","volume":"33","author":"A Joraku","year":"2019","unstructured":"Joraku A, Hatano K, Kawai K, Kandori S, Kojima T, Fukumitsu N, Isobe T, Mori Y, Sakata M, Hara T (2019) Phase I\/IIa PET imaging study with 89zirconium labeled anti-PSMA minibody for urological malignancies. Ann Nucl Med 33:119\u2013127","journal-title":"Ann Nucl Med"},{"key":"2048_CR38","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s11060-018-2825-5","volume":"138","author":"M Matsuda","year":"2018","unstructured":"Matsuda M, Ishikawa E, Yamamoto T, Hatano K, Joraku A, Iizumi Y, Masuda Y, Nishiyama H, Matsumura A (2018) Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody. J Neurooncol 138:581\u2013589","journal-title":"J Neurooncol"},{"key":"2048_CR39","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1021\/bc000092h","volume":"12","author":"PJ Yazaki","year":"2001","unstructured":"Yazaki PJ, Wu AM, Tsai S-W, Williams LE, Ikle\u2019 DN, Wong JY, Shively JE, Raubitschek AA (2001) Tumor targeting of radiometal labeled anti-CEA recombinant T84. 66 diabody and t84. 66 minibody: comparison to radioiodinated fragments. Bioconj Chem 12:220\u2013228","journal-title":"Bioconj Chem"},{"key":"2048_CR40","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1007\/s11307-020-01518-4","volume":"22","author":"W-TK Tsai","year":"2020","unstructured":"Tsai W-TK, Zettlitz KA, Dahlbom M, Reiter RE, Wu AM (2020) Evaluation of [131 I] I-and [177 Lu] Lu-DTPA-A11 minibody for radioimmunotherapy in a preclinical model of PSCA-expressing prostate cancer. Mol Imaging Biol 22:1380\u20131391","journal-title":"Mol Imaging Biol"},{"key":"2048_CR41","doi-asserted-by":"publisher","first-page":"F436","DOI":"10.1152\/ajprenal.1983.244.4.F436","volume":"244","author":"EI Christensen","year":"1983","unstructured":"Christensen EI, Rennke HG, Carone FA (1983) Renal tubular uptake of protein: effect of molecular charge. Am J Physiol Renal Physiol 244:F436\u2013F441","journal-title":"Am J Physiol Renal Physiol"},{"key":"2048_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101295","volume":"15","author":"AS Parihar","year":"2022","unstructured":"Parihar AS, Chopra S, Prasad V (2022) Nephrotoxicity after radionuclide therapies. Transl Oncol 15:101295","journal-title":"Transl Oncol"},{"key":"2048_CR43","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","volume":"51","author":"E Vegt","year":"2010","unstructured":"Vegt E, De Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, Gotthardt M, Boerman OC (2010) Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 51:1049\u20131058","journal-title":"J Nucl Med"},{"key":"2048_CR44","doi-asserted-by":"publisher","first-page":"974","DOI":"10.2967\/jnumed.115.169839","volume":"57","author":"IJ Burvenich","year":"2016","unstructured":"Burvenich IJ, Parakh S, Gan HK, Lee F-T, Guo N, Rigopoulos A, Lee S-T, Gong S, O\u2019Keefe GJ, Tochon-Danguy H (2016) Molecular imaging and quantitation of EphA2 expression in xenograft models with 89Zr-DS-8895a. J Nucl Med 57:974\u2013980","journal-title":"J Nucl Med"},{"key":"2048_CR45","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1007\/s00259-007-0503-5","volume":"34","author":"W Cai","year":"2007","unstructured":"Cai W, Ebrahimnejad A, Chen K, Cao Q, Li Z-B, Tice DA, Chen X (2007) Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging 34:2024\u20132036","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2048_CR46","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.2967\/jnumed.117.192245","volume":"58","author":"O Jacobson","year":"2017","unstructured":"Jacobson O, Li Q, Chen H, Niu G, Kiesewetter DO, Xu L, Cook K, Yang G, Dall\u2019Acqua W, Tsui P (2017) PET-guided evaluation and optimization of internalized antibody\u2013drug conjugates targeting erythropoietin-producing hepatoma A2 receptor. J Nucl Med 58:1838\u20131844","journal-title":"J Nucl Med"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02048-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-025-02048-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02048-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:02:24Z","timestamp":1768413744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-025-02048-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2048"],"URL":"https:\/\/doi.org\/10.1007\/s11307-025-02048-7","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All protocols for mice handling and experiments described in this study were reviewed and approved by University of Missouri-Columbia\u2019s Animal Care and Use Committee (ACUC) and Institutional Biosafety Committee (IBC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval For Animal Studies"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}